MX2023014840A - Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. - Google Patents
Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.Info
- Publication number
- MX2023014840A MX2023014840A MX2023014840A MX2023014840A MX2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A MX 2023014840 A MX2023014840 A MX 2023014840A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- pathway
- combination
- metabolic disorders
- myostatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214234P | 2021-06-23 | 2021-06-23 | |
| US202163260136P | 2021-08-10 | 2021-08-10 | |
| US202163260254P | 2021-08-13 | 2021-08-13 | |
| US202263266348P | 2022-01-03 | 2022-01-03 | |
| US202263269702P | 2022-03-21 | 2022-03-21 | |
| PCT/US2022/034588 WO2022271867A1 (en) | 2021-06-23 | 2022-06-22 | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014840A true MX2023014840A (es) | 2024-02-12 |
Family
ID=82608742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014840A MX2023014840A (es) | 2021-06-23 | 2022-06-22 | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240368262A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4714494A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524159A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022299185A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221555A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4358995T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3062188T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4358995T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309078A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014840A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4358995T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT4358995T (cg-RX-API-DMAC7.html) |
| SI (1) | SI4358995T1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317175A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022271867A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| JP2025532651A (ja) * | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| IL326224A (en) * | 2023-07-31 | 2026-03-01 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025219859A1 (en) * | 2024-04-14 | 2025-10-23 | Biohaven Therapeutics Ltd. | Combination therapy to treat overweight, obesity, and related health conditions |
| WO2025227129A2 (en) | 2024-04-25 | 2025-10-30 | Starrock Pharma Llc | Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
| WO2026037938A1 (en) * | 2024-08-16 | 2026-02-19 | Protuoso Pte. Ltd. | Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor |
| WO2026090182A1 (en) * | 2024-10-23 | 2026-04-30 | Emmyon, Inc. | Glp-1 receptor agonist and ursolic acid combinations and use thereof for increasing weight loss while improving muscle mass and strength |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| EA201891420A1 (ru) | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| HRP20230308T1 (hr) * | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| US20210087250A1 (en) * | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| SG11202108099WA (en) * | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
-
2022
- 2022-06-22 DK DK22744054.2T patent/DK4358995T3/da active
- 2022-06-22 ES ES22744054T patent/ES3062188T3/es active Active
- 2022-06-22 MX MX2023014840A patent/MX2023014840A/es unknown
- 2022-06-22 EP EP25220159.5A patent/EP4714494A3/en active Pending
- 2022-06-22 JP JP2023578073A patent/JP2024524159A/ja active Pending
- 2022-06-22 EP EP22744054.2A patent/EP4358995B1/en active Active
- 2022-06-22 FI FIEP22744054.2T patent/FI4358995T3/fi active
- 2022-06-22 US US18/572,397 patent/US20240368262A1/en active Pending
- 2022-06-22 AU AU2022299185A patent/AU2022299185A1/en active Pending
- 2022-06-22 CA CA3221555A patent/CA3221555A1/en active Pending
- 2022-06-22 PT PT227440542T patent/PT4358995T/pt unknown
- 2022-06-22 SI SI202230232T patent/SI4358995T1/sl unknown
- 2022-06-22 IL IL309078A patent/IL309078A/en unknown
- 2022-06-22 WO PCT/US2022/034588 patent/WO2022271867A1/en not_active Ceased
- 2022-06-22 PL PL22744054.2T patent/PL4358995T3/pl unknown
- 2022-06-23 TW TW111123506A patent/TW202317175A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240368262A1 (en) | 2024-11-07 |
| WO2022271867A1 (en) | 2022-12-29 |
| EP4358995A1 (en) | 2024-05-01 |
| ES3062188T3 (en) | 2026-04-09 |
| FI4358995T3 (fi) | 2026-02-04 |
| PT4358995T (pt) | 2026-02-17 |
| AU2022299185A1 (en) | 2024-01-25 |
| EP4714494A3 (en) | 2026-04-22 |
| PL4358995T3 (pl) | 2026-04-20 |
| DK4358995T3 (da) | 2026-02-02 |
| TW202317175A (zh) | 2023-05-01 |
| JP2024524159A (ja) | 2024-07-05 |
| IL309078A (en) | 2024-02-01 |
| EP4714494A2 (en) | 2026-03-25 |
| SI4358995T1 (sl) | 2026-03-31 |
| CA3221555A1 (en) | 2022-12-29 |
| EP4358995B1 (en) | 2025-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4714494A3 (en) | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders | |
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| MXPA05004110A (es) | Composiciones y metodos para terapia de oxibutinina transdermica. | |
| AR049955A1 (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos | |
| MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
| MX2020013740A (es) | Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular. | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| EA201101191A1 (ru) | Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение | |
| MX342305B (es) | Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina. | |
| MX2020009911A (es) | Usos de inhibiores de dpp iv. | |
| ECSP066268A (es) | Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2020010302A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. | |
| CR20240041A (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con AT2R y/o señalización mediada por AT2R | |
| MX2022014599A (es) | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2021006542A (es) | Inhibidores de la usp19 para usarse en terapia. | |
| MX2025007327A (es) | Nuevo triple agonista de los receptores glp-1/gip/glucagon y composicion farmaceutica para evitar o tratar la obesidad que lo contiene | |
| MX2024004333A (es) | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. | |
| MX2021003980A (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva. | |
| SI1501495T1 (sl) | Uporaba plevromutilinov za zdravljenje motenj, povzročenih s Helicobacter pylori |